Running Point Capital Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Running Point Capital Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,000	Closed	-$124K	–	213
2022 Q4	$124K	Hold	10,000	–	–	0.08%	123
2022 Q3	$140K	Hold	10,000	–	–	0.09%	109
2022 Q2	$138K	Sell	10,000 -11	-0.1%	-$176	0.09%	106
2022 Q1	$163K	Buy	+10,011	New	+$157K	0.1%	103

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Running Point Capital Advisors's ICPT Position: Q1 2023 in Review

Running Point Capital Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2023, closing a stake of 10,000 shares — an estimated $124K sold.

Running Point Capital Advisors first reported a position in ICPT in Q1 2022 and held it in 4 quarters. The position peaked at $163K in Q1 2022. 144 funds tracked by Wall St. Rank hold ICPT as of Q1 2023.

Running Point Capital Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Running Point Capital Advisors sold 10,000 Intercept Pharmaceuticals, Inc. shares in Q1 2023, an estimated $124K.
Running Point Capital Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2022 and held it in 4 quarters.
Running Point Capital Advisors's Intercept Pharmaceuticals, Inc. position peaked at $163K in Q1 2022.
144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2023.

Based on Running Point Capital Advisors's 13F filing for Q1 2023, filed 10 May 2023.